HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Active, not recruiting · NCT03500991 · Registry updated 2025-12-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, atypical teratoid rhabdoid tumor, brain disorder, central nervous system cancer, central nervous system disorder, choroid plexus carcinoma, ependymoma, epithelial neoplasm, glioma, medulloblastoma, mixed neoplasm, neoplasm, nervous system disorder, neuroepithelial neoplasm, pineal body neoplasm, pineoblastoma, primitive neuroectodermal tumor, rhabdoid tumor | Active, not recruiting | Phase 1 | 2025-12-17 | NCT03500991 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Seattle Children's Hospital | 97 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Seattle Children's Hospital | Seattle | United States | 281 |